Loading...
XKRX
298380
Market cap2.00bUSD
Oct 08, Last price  
48,000.00KRW
1D
-6.07%
1Q
-41.32%
IPO
160.16%
Name

ABL Bio Inc

Chart & performance

D1W1MN
XKRX:298380 chart
P/E
—
P/S
33.87
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.17%
Rev. gr., 5y
57.82%
Revenues
79.35b
+137.55%
071,428,5721,257,883,6793,988,956,3928,104,203,4575,332,068,94367,300,799,41365,547,054,62733,403,030,00079,349,848,000
Net income
-37.88b
L-31.79%
-13,684,859,309-74,734,344,037-117,234,140,438-37,004,630,514-55,605,916,023-43,557,942,9853,208,631,000-2,646,663,290-55,529,348,000-37,877,499,000
CFO
-41.25b
L-40.56%
-3,115,032,069-7,142,534,524-12,668,271,640-23,855,091,104-47,294,848,554-40,605,186,98072,131,523,498-28,361,974,590-69,402,667,000-41,253,077,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ABL Bio Inc. is a biotechnology research company based in Seongnam, South Korea. The firm is dedicated to advancing therapeutic medications, primarily concentrating its efforts on treatments for immuno-oncology and neurodegenerative conditions. Its current lineup of investigational drugs features ABL001, various cancer immunotherapies, ADCs, and ABL301.
IPO date
Dec 19, 2018
Employees
Domiciled in
KR
Incorporated in
KR
Headquarters & legal address
경기도 성남시 분당구 대왕판교로712번길 16 (삼평동)
2층
Seongnam-si, 41 13488
KR
Address
16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do
2F.
Seongnam-si, 41 13488
KR
Other language
ABL Bio Inc.

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT